Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? (Q37364425)

19 August 2017

1 reference

title

Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? (English)

1 reference

19 August 2017

1 reference

J R Senior

1

1 reference

PubMed ID

19129750

19 August 2017

language of work or name

English

0 references

publication date

7 January 2009

1 reference

Clinical Pharmacology & Therapeutics

19 August 2017

1 reference

19 August 2017

85

1 reference

19 August 2017

331-334

1 reference

19 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2008.262

19 August 2017

0 references

cites work

Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

The spectrum of hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Transaminase activity in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Is there value in liver function test and creatine phosphokinase monitoring with statin use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Screening in liver disease: report of an AASLD clinical workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Troglitazone-induced liver failure: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

The current state of serum biomarkers of hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Using controlled clinical trials to learn more about acute drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

Hepatic dysfunction associated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

7 January 2021

Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

7 January 2021

Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

7 January 2021

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.262

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.262

1 reference

PubMed ID

19129750

Dimensions Publication ID

19 August 2017

0 references

1 reference

PubMed ID

19129750